Cost-Utility Analysis of Dabrafenib/Trametinib Combination (D+t) for Brafv600 Mutation-Positive Metastatic Melanoma (Mm) From the United Kingdom (Uk) National Health Service (Nhs) Perspective

Value in Health - United Kingdom
doi 10.1016/j.jval.2014.03.414
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Optimizing Combination Dabrafenib and Trametinib Therapy in BRAF Mutation-Positive Advanced Melanoma Patients: Guidelines From Australian Melanoma Medical Oncologists

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2016English

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma

Frontiers in Oncology
Cancer ResearchOncology
2019English

Improved Overall Survival in Melanoma With Combined Dabrafenib and Trametinib

New England Journal of Medicine
Medicine
2015English

Trametinib: A MEK Inhibitor for Management of Metastatic Melanoma

OncoTargets and Therapy
OncologyPharmacology
2015English

Gender, Mentoring and Social Capital in the National Health Service (NHS) in Scotland, UK

Gender, Careers and Inequalities in Medicine and Medical Education: International Perspectives
2015English

A Cost-Utility Analysis of Lighterlife Total as a Treatment for Obesity in the United Kingdom

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Ian Holliday: The National Health Service(NHS) Transformed

Revija Za Socijalnu Politiku
SociologyInternational RelationsPolitical Science
1995English

Cost of the National Health Service

The Lancet
Medicine
1954English

Peritoneal Dialysis and In-Centre Haemodialysis: A Cost-Utility Analysis From a UK Payer Perspective

Applied Health Economics and Health Policy
MedicineHealth PolicyEconomicsEconometrics
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy